Yukiko Onishi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7746026/publications.pdf Version: 2024-02-01



YUKIKO ONISHI

#	Article	IF	CITATIONS
1	Association of insulin treatment with gastric residue during an esophagogastroduodenoscopy. Journal of Diabetes Investigation, 2022, 13, 501-504.	2.4	2
2	Synergistic association of the copper/zinc ratio under inflammatory conditions with diabetic kidney disease in patients with type 2 diabetes: The Asahi Diabetes Complications Study. Journal of Diabetes Investigation, 2022, 13, 299-307.	2.4	14
3	Substitution of telemedicine for clinic visit during the <scp>COVID</scp> â€19 pandemic of 2020: Comparison of telemedicine and clinic visit. Journal of Diabetes Investigation, 2022, 13, 1617-1625.	2.4	7
4	Diabetes management by either telemedicine or clinic visit improved glycemic control during the coronavirus disease 2019 pandemic state of emergency in Japan. Journal of Diabetes Investigation, 2021, , .	2.4	17
5	Associations between diabetes duration and self-stigma development in Japanese people with type 2 diabetes: a secondary analysis of cross-sectional data. BMJ Open, 2021, 11, e055013.	1.9	8
6	Effect of postprandial hyperglycemia at clinic visits on the incidence of retinopathy in patients with typeÂ2 diabetes: An analysis using realâ€world longâ€ŧerm followâ€up data. Journal of Diabetes Investigation, 2020, 11, 930-937.	2.4	8
7	Once-Weekly Dulaglutide with Insulin Therapy for Type 2 Diabetes: Efficacy and Safety Results from a Phase 4, Randomized, Placebo-Controlled Study. Diabetes Therapy, 2020, 11, 133-145.	2.5	6
8	Comparison of twenty indices of insulin sensitivity in predicting type 2 diabetes in Japanese Americans: The Japanese American Community Diabetes Study. Journal of Diabetes and Its Complications, 2020, 34, 107731.	2.3	5
9	How self-stigma affects patient activation in persons with type 2 diabetes: a cross-sectional study. BMJ Open, 2020, 10, e034757.	1.9	27
10	Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen. Diabetes Therapy, 2020, 11, 735-745.	2.5	3
11	1612-P: Insulinogenic Index and HOMA-ß Are Independent Risk Factors for Future Type 2 Diabetes. Diabetes, 2019, 68, .	0.6	0
12	Natural history of impaired glucose tolerance in Japanese Americans: Change in visceral adiposity is associated with remission from impaired glucose tolerance to normal glucose tolerance. Diabetes Research and Clinical Practice, 2018, 142, 303-311.	2.8	1
13	Psychological and behavioural patterns of stigma among patients with type 2 diabetes: a cross-sectional study. BMJ Open, 2017, 7, e013425.	1.9	32
14	Efficacy and safety of dapagliflozin over 1 year as addâ€on to insulin therapy in <scp>J</scp> apanese patients with type 2 diabetes: the <scp>DAISY</scp> (Dapagliflozin Added to patients under InSulin) Tj ETQqO 0	0 ng& T /O	ve do ck 10 Tr
15	Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial. Journal of Diabetes Investigation, 2017, 8, 210-217.	2.4	7
16	Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan. Endocrine Journal, 2017, 64, 553-560.	1.6	19
17	C-Peptide Level in Fasting Plasma and Pooled Urine Predicts HbA1c after Hospitalization in Patients with Type 2 Diabetes Mellitus. PLoS ONE, 2016, 11, e0147303.	2.5	13
18	Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16â€week doubleâ€blind treatment period. Journal of Diabetes Investigation, 2016, 7, 555-564.	2.4	42

Υυκικό Ονιςhi

#	Article	IF	CITATIONS
19	Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes. Endocrine Journal, 2016, 63, 263-273.	1.6	20
20	Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis. Diabetology and Metabolic Syndrome, 2016, 8, 36.	2.7	7
21	Association between self-stigma and self-care behaviors in patients with type 2 diabetes: a cross-sectional study. BMJ Open Diabetes Research and Care, 2016, 4, e000156.	2.8	47
22	Prediction of the effect on antihyperglycaemic action of sitagliptin by plasma active form glucagon-like peptide-1. World Journal of Diabetes, 2016, 7, 230.	3.5	3
23	Efficacy and safety of lixisenatide in Japanese patients with typeÂ2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of <scp>G</scp> et <scp>G</scp> oalâ€ <scp>S</scp> . Journal of Diabetes Investigation, 2015, 6, 201-209.	2.4	11
24	Optimum BMI Cut Points to Screen Asian Americans for Type 2 Diabetes. Diabetes Care, 2015, 38, 814-820.	8.6	108
25	Role of elevated serum uric acid levels at the onset of overt nephropathy in the risk for renal function decline in patients with typeÂ2 diabetes. Journal of Diabetes Investigation, 2015, 6, 98-104.	2.4	31
26	Serum butyrylcholinesterase and the risk of future type 2 diabetes: the Kansai Healthcare Study. Clinical Endocrinology, 2014, 80, 362-367.	2.4	29
27	Safety of exenatide once weekly for 52Âweeks in <scp>J</scp> apanese patients with type 2 diabetes mellitus. Journal of Diabetes Investigation, 2013, 4, 182-189.	2.4	11
28	Twentyâ€year trend of increasing obesity in young patients with poorly controlled type 2 diabetes at first diagnosis in urban <scp>J</scp> apan. Journal of Diabetes Investigation, 2013, 4, 540-545.	2.4	22
29	Insulin degludec compared with insulin glargine in insulinâ€naÃ⁻ve patients with type 2 diabetes: <scp>A</scp> 26â€week, randomized, controlled, <scp>P</scp> anâ€ <scp>A</scp> sian, treatâ€toâ€target trial. Journal of Diabetes Investigation, 2013, 4, 605-612.	2.4	90
30	Efficacy and safety of exenatide onceâ€weekly vs exenatide twiceâ€daily in <scp>A</scp> sian patients with type 2 diabetes mellitus. Journal of Diabetes Investigation, 2013, 4, 53-61.	2.4	72
31	Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2010, 89, 216-223.	2.8	49
32	Fasting tests of insulin secretion and sensitivity predict future prediabetes in Japanese with normal glucose tolerance. Journal of Diabetes Investigation, 2010, 1, 191-195.	2.4	49
33	A Novel Protein Kinase B (PKB)/AKT-binding Protein Enhances PKB Kinase Activity and Regulates DNA Synthesis. Journal of Biological Chemistry, 2005, 280, 18525-18535.	3.4	113
34	Hepatic Akt Activation Induces Marked Hypoglycemia, Hepatomegaly, and Hypertriglyceridemia With Sterol Regulatory Element Binding Protein Involvement. Diabetes, 2003, 52, 2905-2913.	0.6	149
35	Differing Roles of Akt and Serum- and Glucocorticoid-regulated Kinase in Glucose Metabolism, DNA Synthesis, and Oncogenic Activity. Journal of Biological Chemistry, 2003, 278, 25802-25807.	3.4	108
36	Three Mitogen-Activated Protein Kinases Inhibit Insulin Signaling by Different Mechanisms in 3T3-L1 Adipocytes. Molecular Endocrinology, 2003, 17, 487-497.	3.7	171

Υυκικό Ονιςhi

#	Article	IF	CITATIONS
37	Humoral Regulation of Resistin Expression in 3T3-L1 and Mouse Adipose Cells. Diabetes, 2002, 51, 1737-1744.	0.6	195
38	High-Salt Diet Enhances Insulin Signaling and Induces Insulin Resistance in Dahl Salt-Sensitive Rats. Hypertension, 2002, 40, 83-89.	2.7	147
39	Angiotensin Il–Induced Insulin Resistance Is Associated With Enhanced Insulin Signaling. Hypertension, 2002, 40, 872-879.	2.7	248
40	Activation of AMPK is essential for AICAR-induced glucose uptake by skeletal muscle but not adipocytes. American Journal of Physiology - Endocrinology and Metabolism, 2002, 282, E1239-E1244.	3.5	75
41	Resistin is regulated by C/EBPs, PPARs, and signal-transducing molecules. Biochemical and Biophysical Research Communications, 2002, 299, 291-298.	2.1	57
42	Five isoforms of the phosphatidylinositol 3-kinase regulatory subunit exhibit different associations with receptor tyrosine kinases and their tyrosine phosphorylations. FEBS Letters, 2001, 490, 32-38.	2.8	39
43	MKK6/3 and p38 MAPK Pathway Activation Is Not Necessary for Insulin-induced Glucose Uptake but Regulates Glucose Transporter Expression. Journal of Biological Chemistry, 2001, 276, 19800-19806.	3.4	111
44	Regulation of Phosphoinositide Metabolism, Akt Phosphorylation, and Glucose Transport by PTEN (Phosphatase and Tensin Homolog Deleted on Chromosome 10) in 3T3-L1 Adipocytes. Molecular Endocrinology, 2001, 15, 1411-1422.	3.7	68
45	The N-terminal 34 residues of the 55ÂkDa regulatory subunits of phosphoinositide 3-kinase interact with tubulin. Biochemical Journal, 2000, 346, 483.	3.7	7
46	The N-terminal 34 residues of the 55ÂkDa regulatory subunits of phosphoinositide 3-kinase interact with tubulin. Biochemical Journal, 2000, 346, 483-489.	3.7	37
47	lmidapril, an angiotensin-converting enzyme inhibitor, improves insulin sensitivity by enhancing signal transduction via insulin receptor substrate proteins and improving vascular resistance in the Zucker fatty rat. Metabolism: Clinical and Experimental, 1999, 48, 1248-1255.	3.4	76
48	Different Subcellular Distribution and Regulation of Expression of Insulin Receptor Substrate (IRS)-3 from Those of IRS-1 and IRS-2. Journal of Biological Chemistry, 1998, 273, 29686-29692.	3.4	63
49	Systemic Sarcoidosis with Significant Granulomatous Swelling of the Pharyngeal Tonsil Internal Medicine, 1998, 37, 157-160.	0.7	9
50	14-3-3 Protein Binds to Insulin Receptor Substrate-1, One of the Binding Sites of Which Is in the Phosphotyrosine Binding Domain. Journal of Biological Chemistry, 1997, 272, 25267-25274.	3.4	141